Transport
CH Allied Services, INC.
CH Allied Services, INC. was paid $8.56M by Medicaid between Jan 2018 and Dec 2024, across 72 billing codes. Its largest line is A0427, emergency ambulance ride, advanced life support — 22% of everything it billed.
33Billing provider infoCH ALLIED SERVICES, INC.
COLUMBIA, MO 65201
COLUMBIA, MO 65201
33aNPI1902817844assigned 08/09/2006
33bProvider typeAmbulance
28Total paid$8.56M
24GClaims115,490
24DCodes billed72
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulance providers in Missouri
Rank by total paid#6 of 54
Median peer was paid$537K
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,306 | $1.12M | |
| 2019 | 9,080 | $1.07M | |
| 2020 | 9,947 | $941K | |
| 2021 | 14,716 | $843K | |
| 2022 | 22,972 | $1.53M | |
| 2023 | 27,566 | $1.76M | |
| 2024incomplete | 19,903 | $1.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 22% | 7,352 | 6,344 | $1.92M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 11,414 | 10,296 | $1.36M |
| X4011 | State-specific procedure code | 15% | 3,539 | 3,239 | $1.28M |
| A0425 | Ground mileage, per statute mile | 7.2% | 11,422 | 9,353 | $616K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 6.7% | 2,378 | 2,006 | $577K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 6.1% | 6,595 | 3,439 | $524K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.6% | 18,047 | 16,503 | $398K |
| 80053 | Comprehensive metabolic panel | 4.6% | 17,155 | 15,667 | $396K |
| X4006 | 3.2% | 791 | 494 | $276K | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.5% | 997 | 893 | $216K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 1,769 | 1,579 | $173K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 3,270 | 2,790 | $133K |
60 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 3,237 | $110K |
| 99284 | Emergency room visit (serious) | 1.1% | 565 | $91K |
| 97597 | 1.0% | 2,162 | $89K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 938 | $58K |
| Y7506 | <1% | 531 | $41K | |
| X4003 | <1% | 743 | $41K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 765 | $35K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 741 | $29K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,834 | $26K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 346 | $20K |
| 81001 | <1% | 4,261 | $19K | |
| Y7507 | <1% | 143 | $18K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 892 | $14K |
| 84484 | <1% | 1,140 | $12K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 148 | $8K |
| 80061 | Lipid panel | <1% | 752 | $8K |
| 62323 | <1% | 140 | $8K | |
| 43253 | <1% | 17 | $8K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 408 | $7K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 249 | $7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 965 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 103 | $6K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 68 | $5K |
| 83655 | <1% | 663 | $4K | |
| 83690 | <1% | 35 | $4K | |
| 84439 | <1% | 75 | $4K | |
| 87070 | <1% | 761 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 84 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 47 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 45 | $2K |
| 62321 | <1% | 30 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 197 | $1K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 348 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 551 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 14 | $1K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 16 | $949.92 |
| 87040 | <1% | 38 | $601.21 | |
| 85014 | <1% | 519 | $532.42 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 14 | $485.00 |
| 86850 | <1% | 66 | $472.17 | |
| 86900 | <1% | 161 | $459.73 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 14 | $414.41 |
| 83880 | <1% | 26 | $368.10 | |
| 84703 | <1% | 90 | $362.49 | |
| 83605 | <1% | 44 | $319.20 | |
| 86901 | <1% | 159 | $255.12 | |
| 85610 | <1% | 86 | $146.59 | |
| 36416 | <1% | 62 | $137.55 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 29 | $122.48 |
| 81025 | <1% | 25 | $34.40 | |
| 85730 | <1% | 14 | $29.65 | |
| 81003 | <1% | 13 | $9.00 | |
| J3490 | Unclassified drugs | 0% | 1,093 | $0.00 |
| 11045 | 0% | 22 | $0.00 | |
| 87430 | 0% | 13 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 55 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 21 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 112 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 13 | $0.00 |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 0% | 58 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHAMBERS, BARRY (CFO)
| Provider | Location | Paid |
|---|---|---|
| Chas Physician Services LLC | Columbia, MO | $273K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.